S194: INTEGRATIVE CLINICAL PROTEOTYPING AND DRUG RESPONSE PROFILING IDENTIFIES TARGETABLE BIOLOGY UNDERLYING MYELOPROLIFERATIVE NEOPLASMS

• M. H. Wildschut,
• M. van Oostrum,
• J. Settelmeier,
• J. Mena,
• C. Dördelmann,
• Y. Festl,
• A. Ring,
• R. C. Skoda,
• M. Lopes,
• B. Wollscheid,
• B. Snijder,
• A. Theocharides

Affiliations

M. H. Wildschut

1 Institute of Molecular Systems Biology, Department of Biology

M. van Oostrum

2 Institute of Translational Medicine, Department of Health Science and Technology, ETH Zurich

J. Settelmeier

2 Institute of Translational Medicine, Department of Health Science and Technology, ETH Zurich

J. Mena

1 Institute of Molecular Systems Biology, Department of Biology

C. Dördelmann

5 Insititute of Molecular Cancer Research, University of Zurich, Zurich

Y. Festl

1 Institute of Molecular Systems Biology, Department of Biology

A. Ring

3 Department of Medical Oncology and Hematology, Division of Hematology, University Hospital Zurich, Zurich

R. C. Skoda

6 Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Basel, Switzerland

M. Lopes

5 Insititute of Molecular Cancer Research, University of Zurich, Zurich

B. Wollscheid

2 Institute of Translational Medicine, Department of Health Science and Technology, ETH Zurich

B. Snijder

1 Institute of Molecular Systems Biology, Department of Biology

A. Theocharides

3 Department of Medical Oncology and Hematology, Division of Hematology, University Hospital Zurich, Zurich